Internal Medicine, Rheumatology · Okemos, MI
NPI
1295852895
Since 2007
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
2375 Woodlake Dr Ste 300
Okemos, MI, 48864
Phone (517) 908-3600
Groups this clinician bills Medicare through
Medicare paid, 2024
$975K
86,788 services
Medicare patients, 2024
431
Average age 71
Drug cost, 2024
$4.6M
3,513 prescriptions
Company payments, 2025
$6,018
From 23 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Monika Mohan was code J1602 (injection, golimumab, 1 mg, for intravenous use), 20,951 times for 36 patients. In total Monika Mohan billed 86,788 services in 35 codes, and Medicare paid $975K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-07-01.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 20,951 | 36 | $8.85 | $185K |
| J0717 Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 18,801 | 13 | $3.59 | $67K |
| J3111 Injection, romosozumab-aqqg, 1 mg | Office | 13,650 | 15 | $8.39 | $115K |
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 3,825 | 12 | $31.50 | $120K |
| J0897 Injection, denosumab, 1 mg | Office | 3,480 | 45 | $20.41 | $71K |
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 1,608 | 21 | $0.10 | $153 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 472 | 309 | $11.71 | $5,528 |
| 99214 Office E&M - Established | Office | 391 | 256 | $78.53 | $31K |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 308 | 37 | $0.74 | $227 |
| 96413 Chemotherapy Administration | Office | 303 | 72 | $89.98 | $27K |
| 99213 Office E&M - Established | Office | 214 | 178 | $60.66 | $13K |
| 96372 Injection Administration | Office | 151 | 78 | $10.44 | $1,577 |
| 96401 Chemotherapy Administration | Office | 96 | 13 | $51.72 | $4,965 |
| 99204 Office E&M - New | Office | 80 | 80 | $106.67 | $8,534 |
| J3489 Injection, zoledronic acid, 1 mg | Office | 65 | 13 | $5.17 | $336 |
By year: 2022 $979K for 76,688 services; 2023 $981K for 73,130 services; 2024 $975K for 86,788 services.
Medicare prescription drug claims, 2024
In 2024, the drug Monika Mohan prescribed most often to Medicare patients was Hydroxychloroquine Sulfate, with 720 prescriptions and refills. In total Monika Mohan wrote 3,513 Medicare prescriptions that cost $4.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydroxychloroquine Sulfate Generic | 720 | 1,727 | 227 | $47K |
| Methotrexate Methotrexate Sodium | 431 | 879 | 122 | $16K |
| Prednisone Generic | 415 | 844 | 195 | $4,450 |
| Sulfasalazine Dr Sulfasalazine | 163 | 327 | 51 | $10K |
| Celecoxib Generic | 160 | 341 | 50 | $6,874 |
| Sulfasalazine Generic | 145 | 340 | 54 | $7,031 |
| Meloxicam Generic | 111 | 280 | 43 | $921 |
| Enbrel Etanercept | 90 | 90 | 15 | $657K |
| Humira(Cf) Adalimumab | 80 | 85 | 11 | $566K |
| Otezla Apremilast | 74 | 74 | Under 11 | $357K |
| Azathioprine Generic | 70 | 126 | 12 | $4,853 |
| Humira(Cf) Pen Adalimumab | 61 | 75 | 11 | $529K |
| Enbrel Sureclick Etanercept | 55 | 55 | Under 11 | $425K |
| Methotrexate Sodium Methotrexate Sodium/Pf | 52 | 93 | 21 | $1,120 |
| Alendronate Sodium Generic | 48 | 95 | 14 | $408 |
Brand drugs: 1,037 claims; generic drugs: 2,412 claims; opioid claims: 37.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Monika Mohan $6,018 ($6,018 in general payments such as food, travel and fees) from 23 companies. The largest payer was Amgen Inc. with $3,408.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 29 | $3,408 |
| Abbvie Inc. ABBV | 35 | $406 |
| UCB, Inc. UCB.BR | 22 | $377 |
| Janssen Biotech, Inc. JNJ | 19 | $370 |
| E.R. Squibb & Sons, L.L.C. BMY | 9 | $261 |
| AstraZeneca Pharmaceuticals LP AZN | 8 | $184 |
| Genzyme Corporation SNY | 10 | $177 |
| Novartis Pharmaceuticals Corporation NVS | 12 | $173 |
| Fresenius Kabi USA, LLC | 5 | $140 |
| Pfizer Inc. PFE | 9 | $118 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.